Antidepressive Agents, Second-Generation
-
Subject Areas on Research
-
A Pilot Trial Examining African American and White Responses to Algorithm-Guided Smoking Cessation Medication Selection in Persons Living with HIV.
-
A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
-
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
-
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
-
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
-
A possible role of recurrent major depression in risk of fracture.
-
A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder.
-
A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
-
Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
-
Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.
-
Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression.
-
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
-
An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
-
Antidepressant-like effects of cranial stimulation within a low-energy magnetic field in rats.
-
Antidepressants in pregnancy: a review of commonly prescribed medications.
-
Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.
-
Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.
-
Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia.
-
Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
-
Bupropion SR in the naturalistic treatment of elderly patients with major depression.
-
Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
-
Bupropion and guanfacine.
-
Bupropion in the treatment of outpatients with asthma and major depressive disorder.
-
Bupropion sustained release: a therapeutic overview.
-
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
-
CYP2C19 variation and citalopram response.
-
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
-
Clinical use of nefazodone in major depression: a 6-year perspective.
-
Clinician, parent, and child prediction of medication or placebo in double-blind depression study.
-
Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial.
-
Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.
-
Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.
-
Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.
-
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
-
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
-
Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
-
Daily process methodology for measuring earlier antidepressant response.
-
Depression and insomnia in women.
-
Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D.
-
Depression treatment in patients with general medical conditions: results from the CO-MED trial.
-
Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals.
-
Determination of sulpiride by capillary electrophoresis with end-column electrogenerated chemiluminescence detection.
-
Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.
-
Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.
-
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.
-
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.
-
Diurnal mood variation in outpatients with major depressive disorder.
-
Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
-
Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior?
-
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
-
Does pretreatment insomnia or anxiety predict acute response to bupropion SR?
-
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
-
Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial.
-
Dropouts versus completers among chronically depressed outpatients.
-
Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression.
-
Effect of Extended Release Bupropion on Unilateral Ultrabrief Electroconvulsive Therapy Seizure Parameters in Major Depressive Disorder.
-
Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
-
Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study.
-
Effect of selective serotonin reuptake inhibitors on the risk of fracture.
-
Effects of fluoxetine on the polysomnogram in outpatients with major depression.
-
Effects of paroxetine and venlafaxine XR on heart rate variability in depression.
-
Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.
-
Efficacy of newer medications for treating depression in primary care patients.
-
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
-
Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants.
-
Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS).
-
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
-
Ethnicity/race and outcome in the treatment of depression: results from STAR*D.
-
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
-
Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report.
-
Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.
-
Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
-
Fluoxetine in child and adolescent depression: acute and maintenance treatment.
-
Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study.
-
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder.
-
Fluoxetine reduces saccharin-induced elevation of fluid intake in alcohol-preferring Fawn-Hooded rats.
-
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
-
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
-
Fluvoxamine in civilians with posttraumatic stress disorder.
-
Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
-
Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients.
-
Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?
-
Guideline-concordant antidepressant use among patients with major depressive disorder.
-
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
-
Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
-
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
-
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
-
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
-
Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans.
-
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers.
-
Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
-
MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression.
-
Misidentification of Bupropion Glucuronide Metabolites and Re-evaluation of Metabolite Pharmacokinetics.
-
Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder.
-
Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus aged rats.
-
Molecular genetics of successful smoking cessation: convergent genome-wide association study results.
-
Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis.
-
Nefazodone in post-traumatic stress disorder: results from six open-label trials.
-
New drugs for old folks: the evidence-based argument for newer antidepressants.
-
Off-label applications for SSRIs.
-
Open trial of nefazodone for combat-related posttraumatic stress disorder.
-
Outcomes from an outpatient smoking-cessation clinic.
-
Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
-
Overview of psychiatric disorders and the role of newer antidepressants.
-
Paroxetine as a treatment for premenstrual dysphoric disorder.
-
Paroxetine in the treatment of generalised anxiety disorder.
-
Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication.
-
Pharmacological and surgical treatments for obesity.
-
Potential fluoxetine chloride (Prozac) toxicity in a newborn.
-
Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study.
-
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
-
Predictors of hopelessness among clinically depressed youth.
-
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
-
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.
-
Psychotic disorder in a patient with central and extrapontine myelinolysis.
-
Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine.
-
Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders.
-
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
-
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
-
Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers.
-
Recovery and recurrence following treatment for adolescent major depression.
-
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
-
Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
-
Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.
-
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
-
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
-
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder.
-
Reversible nefazodone-induced liver failure.
-
Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study.
-
SLC6A4 variation and citalopram response.
-
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
-
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.
-
Serotonin syndrome after a massive overdose of controlled-release paroxetine.
-
Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.
-
Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.
-
Sex differences in response to citalopram: a STAR*D report.
-
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.
-
Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?
-
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
-
Social problem-solving among adolescents treated for depression.
-
St John's for depression, worts and all.
-
Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
-
Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS.
-
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
-
Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.
-
Suicide in pregnancy.
-
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
-
The effects of extended evaluation on depressive symptoms in children and adolescents.
-
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression.
-
The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder.
-
The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice.
-
The impact of neuropsychological functioning on treatment outcome in pediatric obsessive-compulsive disorder.
-
The impact of nonclinical factors on care use for patients with depression: a STAR*D report.
-
The role of readiness to change in response to treatment of adolescent depression.
-
Therapeutic reactance as a predictor of outcome in the treatment of chronic depression.
-
Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
-
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
-
Treating depression and oppositional behavior in adolescents.
-
Treatment of depression--newer pharmacotherapies.
-
Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.
-
Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
-
Treatment of mild depression in elderly patients.
-
Treatment of posttraumatic stress disorder with nefazodone.
-
Treatment of posttraumatic stress disorder: the impact of paroxetine.
-
Treatment outcome variation between depression symptom combinations in the STAR*D study.
-
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
-
Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial).
-
Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
-
What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
-
When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.
-
Which depressed patients respond to nefazodone and when?
-
[A new quality of the therapy of anxiety and depression--escitalopram].
-
Keywords of People